Did peptides or PEDs contribute to Bostin Loyd's kidney failure?

What did @aideasprompted actually say?

The creator described a compound called "atopoatide" (almost certainly adipotide, also known as FTPP) as a drug that kills fat cells by binding to a protein called "prohibitin" on their surface, cutting off blood supply and triggering apoptosis. They also said the same protein exists on kidney cells, which is why kidney failure appeared as a side effect in clinical trials.

The video is framed around the death of bodybuilder Bostin Loyd and appears to suggest adipotide may have played a role. That's a serious claim, and the mechanism described is largely accurate for what adipotide actually does, though the word "prohibiting" used in the transcript is a mangled pronunciation of prohibitin, a real mitochondrial protein. The core science here is not invented. It is, however, incomplete in ways that matter.

Does the science back this up?

Mostly, yes, but with important caveats. Adipotide (FTPP) is a peptidomimetic compound, meaning it mimics peptide behavior, and it was studied in primates and obese rhesus monkeys. The 2011 Kolonin et al. study in Science Translational Medicine showed significant fat loss in obese monkeys alongside improved insulin sensitivity. The prohibitin-targeting mechanism is real.

The kidney toxicity concern is also documented. Prohibitin is expressed in kidney tubular cells, and the compound's mechanism does not discriminate perfectly between fat vasculature and renal vasculature. A 2011 paper by Barnhart et al. in the Proceedings of the National Academy of Sciences confirmed prohibitin as a vascular marker in adipose tissue but also flagged the dual expression problem. Human clinical trials were conducted, and renal toxicity was reported, which contributed to why this drug never cleared development. Saying it "disrupts the blood supply to fat cells" is an accurate plain-language description of apoptosis via vascular targeting.

What did they get wrong (or right)?

They got the mechanism broadly right. The prohibitin-binding explanation, the apoptosis pathway, and the kidney failure link are all real. Credit where it is due.

What they got wrong, or at least sloppy about: the phrase "clinical trials" is used loosely. Adipotide progressed through early-phase human research, but it never completed large-scale randomized controlled trials. Describing the evidence base as "clinical trials" without that context overstates how far the drug actually got. The creator also says kidney failure was "observed," which implies a clean signal, but the renal side effects varied in severity and were more accurately described as dose-dependent nephrotoxicity rather than outright failure in all subjects.

The implied connection to Bostin Loyd's death is also worth flagging. Loyd used many compounds, and attributing his kidney failure specifically to adipotide without autopsy or toxicological evidence is speculation, not science.

What should you actually know?

Adipotide represents a genuinely interesting and genuinely risky class of research compounds. It is not a peptide in the conventional sense used in most peptide therapy discussions. It is a peptidomimetic, meaning a synthetic compound designed to mimic peptide binding behavior. That distinction matters when people in bodybuilding communities discuss it alongside BPC-157 or TB-500, which have different safety profiles and mechanisms.

Prohibitin is not a simple on-off switch for fat cells. It plays roles in mitochondrial function, cell signaling, and apoptosis regulation across multiple tissue types. Targeting it systemically is not like targeting a receptor expressed only in one tissue. This is precisely why selective vascular targeting, which was the goal of FTPP design, is so difficult to achieve without collateral damage.

If you are seeing adipotide sold in any gray-market peptide context, that is not a research compound with a safety profile. It is a compound that failed human development partly because the kidney risk was real and not fully controllable at therapeutic doses. Anyone presenting it as a fat-loss tool without that context is leaving out the part that matters most.